Importantly, CQ has been used to overcome resistance of lung carcinoma cells to different chemotheraputics such as the dual PI3K/mTOR inhibitor PI103 and crizotinib [45, 46], while rapamycin has been administrated in a phase I trial of patients with advanced non-small cell lung cancer [47]. This evidence concerns the gene MTOR and lung carcinoma.